Revive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19

Jan 6, 2022

Approximately 700 subjects participated in the enrollment period Expected to begin subject enrollment in Turkey by mid-February Expected to complete enrollment in Q1-2022 TORONTO, Jan. 06, 2022 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB:...

PharmaDrug Announces Addition of Dr. Cindy Hutnik, President of the Canadian Glaucoma Society to Their Scientific Advisory Board to Enhance Ongoing DMT Studies to Treat Glaucoma

Dec 13, 2021

Toronto, Ontario –  December 13, 2021- PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural...

Kontrol Technologies Secures Multi-Year Service Agreements for 18 New Buildings

Dec 10, 2021

Continued Expansion of Building Customers Supports Growing Recurring Revenue Base Toronto, ON, December 10, 2021 – Kontrol Technologies Corp. (NEO:KNR) (OTCQB:KNRLF) (FSE:1K8) (“Kontrol” or the “Company”), a leader in smart building technology, secured multi-year...

Kontrol Technologies Advances Net Zero Building Infrastructure with Launch of SmartPower® Energy as a Service

Dec 6, 2021

Begins Quoting Large-Scale Building Applications with a Focus on Recurring Revenues and Monetization of Carbon Credits  TORONTO, ONTARIO – December 6, 2021 – Kontrol Technologies Corp. (NEO:KNR) (OTCQB:KNRLF) (FSE:1K8) (“Kontrol” or the...

UPDATE — Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial

Dec 3, 2021

Expanding the potential of Bucillamine as an effective treatment for Omicron variant (B.1.1.529) Bucillamine shown to inhibit SARS-CoV-2 infection in vitro for the Delta variant (B.1.617.2) Adding inflammatory markers along with viral load testing to current Phase 3...

Pharmadrug Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Development of Its Cepharanthine for Treatment of Mild to Moderate COVID-19 Infection

Nov 30, 2021

Established alignment with FDA on the path forward for the development of PD-001, a patented enteric-coated formulation of cepharanthine, towards clinical studies for mild-moderate COVID-19 infection Meeting response validates CMC package for PD-001 as an oral...